• Mashup Score: 4
    CTG Labs - NCBI - 2 year(s) ago

    Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

    Tweet Tweets with this article
    • Proud @WiscPediatrics @UWCarbone @UWHealth to be the only US site collaborating with Dr Gray on this innovative trial combining MIBG, anti-PD1 and anti-GD2 #neuroblastoma 1st transatlantic trial #childhoodcancerawarenessmonth https://t.co/MDxJN4tEuJ https://t.co/bZkkqYK2c1

  • Mashup Score: 1

    Job Summary: The Division of Hematology, Oncology and Bone Marrow Transplant within the Department of Pediatrics at the University of Wisconsin School of Medicine and Public Health is recruiting a Bone Marrow Transplant Physician. We are looking for candidates with a track record of clinical excellence and academic contributions as demonstrated through training and/or practice experience in…

    Tweet Tweets with this article
    • We are hiring a Director of Pediatric Stem Cell Transplant/Cell Therapy @WiscPediatrics @UWCarbone @UWHealth #AmericanFamilyChildrensHospital Interest in clinical or translational research preferred. Join a great team in a great capital! Please apply: https://t.co/4GL8vs037j

  • Mashup Score: 0
    UW Health Careers - 2 year(s) ago

    Tweet Tweets with this article
    • We are hiring a Pediatric Clinical Nurse Specialist to support the great nurses in our cancer and blood disorders program. Opportunities for enhancing QI and education in #BMT #CARTcells #immunotherapy #targetedradiotherapy @UWHealth Apply here: https://t.co/zxLcFS7Tjq

  • Mashup Score: 0

    Treatment of relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) remains a challenge, particularly in patients who do not respond to traditional chemotherapy or immunotherapy. The objective of this study was to assess the efficacy of fedratinib, a semi selective JAK2 inhibitor and venetoclax, a selective BCL-2 inhibitor, on human B-ALL using both single-agent and combinatorial…

    Tweet Tweets with this article
    • Congratulations to rising star @UWICTR graduate student Sean Rinella @WiscPediatrics @UWCarbone for showing that JAK2 inhibitor fedratinib and BCL2 inhibitor venetoclax synergize to treat FLT3+ B-ALL #leukemia CD19 expression goes way up too! https://t.co/cR1EbOiP1h

  • Mashup Score: 0

    Background: Osteosarcoma (OS) patients that present with metastatic disease have a poor prognosis and no curative options. Allogeneic bone marrow transplant (alloBMT) is curative for hematologic malignancies through the graft-versus-tumor (GVT) effect, but to date has been ineffective for solid tumors like OS. CD155 is expressed on OS and interacts strongly with the inhibitory receptors TIGIT and…

    Tweet Tweets with this article
    • Her work is on @biorxivpreprint Using Ly49-mismatched allogeneic #NKcells with anti-CD155 after #BMT kills relapsed #osteosarcoma in a DNAM-1 dependent manner. If you block DNAM-1, NKG2D emerges but is not sufficient for lysis despite ligands in lung TME https://t.co/HYGu9xmmjk

  • Mashup Score: 4

    Job Summary: The Division of Hematology, Oncology and Bone Marrow Transplant within the Department of Pediatrics at the University of Wisconsin School of Medicine and Public Health is recruiting a Pediatric Neuro Oncologist with an interest and expertise in neuro-oncology and neurocutaneous disorders. We are looking for candidates with a track record of clinical excellence and academic…

    Tweet Tweets with this article
    • We are hiring a Pediatric Neuro-Oncologist with interest in clinical/translational research @WiscPediatrics @UWCarbone @UWHealth #AmericanFamilyChildrensHospital We have comprehensive brain tumor and neurocutaneous disorders clinics in place. DM or apply: https://t.co/iH14F2fkyz

  • Mashup Score: 1

    Dexrazoxane appeared to have a cardioprotective effect almost 2 decades after exposure to anthracyclines among a cohort of young adults who survived childhood cancer, according to study results published in Journal of Clinical Oncology.Researchers primarily observed the effect of dexrazoxane among those treated with cumulative doses of doxorubicin of 250 mg/m² or higher.

    Tweet Tweets with this article
    • RT @HemOncToday: Dexrazoxane confers long-term cardioprotection after anthracyclines for pediatric cancer. https://t.co/KNpXUZgPnC #Pediat…